Brief: Annovis Secures U.S. Patent For Buntanetap In The Prevention And Treatment Of Neurological Injuries Caused By Brain Infections
02/04/2026 13:16
April 2 (Reuters) - Annovis Bio Inc ANVS.N: ANNOVIS SECURES U.S. PATENT FOR BUNTANETAP IN THE PREVENTION AND TREATMENT OF NEUROLOGICAL INJURIES CAUSED BY BRAIN INFECTIONS Source text: ID:nGNX2PSsmL Further company coverage: ANVS.N ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Annovis Bio
See all newsAnnovis Bio Inc reports results for the quarter ended June 30 - Earnings Summary
Annovis Bio Q2 loss widens as R&D costs rise
Annovis Bio Inc expected to post a loss of 45 cents a share - Earnings Preview
Brief: Annovis Announces Pricing Of $15.0 Million Public Offering Of Common Stock And Accompanying Warrants
U.S. STOCKS ON THE MOVE-Amazon, Northrop Grumman, Brown-Forman